The choice of the moAb lies between drugs directed against the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor receptor (VEGFR), according to the patient characteristics, tumor molecular profile, and primary tumor location [3,4,5,6,7,8]. This evidence concerns the gene EGFR and neoplasm.